147 related articles for article (PubMed ID: 15749642)
1. [Preclinical models of prostate cancer].
Fizazi K; Navone NM
Bull Cancer; 2005 Feb; 92(2):129-41. PubMed ID: 15749642
[TBL] [Abstract][Full Text] [Related]
2. Establishment of two human prostate cancer cell lines derived from a single bone metastasis.
Navone NM; Olive M; Ozen M; Davis R; Troncoso P; Tu SM; Johnston D; Pollack A; Pathak S; von Eschenbach AC; Logothetis CJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2493-500. PubMed ID: 9815652
[TBL] [Abstract][Full Text] [Related]
3. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; RĂ©dini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
4. In vivo models of prostate cancer metastasis to bone.
Singh AS; Figg WD
J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963
[TBL] [Abstract][Full Text] [Related]
5. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
7. A metastatic human prostate cancer model using intraprostatic implantation of tumor produced by PC-3 neolacZ transfected cells.
Tsingotjidou AS; Ahluwalia R; Zhang X; Conrad H; Emmanouilides C
Int J Oncol; 2003 Dec; 23(6):1569-74. PubMed ID: 14612928
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
9. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research.
Klein RD
Mutat Res; 2005 Aug; 576(1-2):111-9. PubMed ID: 15885713
[TBL] [Abstract][Full Text] [Related]
10. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
[TBL] [Abstract][Full Text] [Related]
11. A Nod Scid mouse model to study human prostate cancer.
Bastide C; Bagnis C; Mannoni P; Hassoun J; Bladou F
Prostate Cancer Prostatic Dis; 2002; 5(4):311-5. PubMed ID: 12627217
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Singh AS; Macpherson GR; Price DK; Schimel D; Figg WD
Oncol Rep; 2006 Mar; 15(3):519-24. PubMed ID: 16465406
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of metastatic potential in prostate carcinoma: an in vivo model.
Angelucci A; Gravina GL; Rucci N; Festuccia C; Muzi P; Vicentini C; Teti A; Bologna M
Int J Oncol; 2004 Dec; 25(6):1713-20. PubMed ID: 15547709
[TBL] [Abstract][Full Text] [Related]
14. [In vitro and in vivo models developed from human prostatic cancer].
Bladou F; Gleave ME; Penault-Llorca F; Serment G; Lange PH; Vessella RL
Prog Urol; 1997 Jun; 7(3):384-96. PubMed ID: 9273065
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two in vivo models for prostate cancer: orthotopic and intratesticular inoculation of LNCaP or PC-3 cells.
Koshida K; Konaka H; Imao T; Egawa M; Mizokami A; Namiki M
Int J Urol; 2004 Dec; 11(12):1114-21. PubMed ID: 15663685
[TBL] [Abstract][Full Text] [Related]
16. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.
Bisanz K; Yu J; Edlund M; Spohn B; Hung MC; Chung LW; Hsieh CL
Mol Ther; 2005 Oct; 12(4):634-43. PubMed ID: 16039164
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.
Singh LS; Berk M; Oates R; Zhao Z; Tan H; Jiang Y; Zhou A; Kirmani K; Steinmetz R; Lindner D; Xu Y
J Natl Cancer Inst; 2007 Sep; 99(17):1313-27. PubMed ID: 17728215
[TBL] [Abstract][Full Text] [Related]
18. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
19. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]